Markets:

Overview

News

Currencies

International

Treasuries

Prothena Corporation plc - Ordinary Shares (NQ:PRTA)

9.850 +0.170 (+1.76%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Prothena Corporation plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Prothena Reports First Quarter 2023 Financial Results and Business Highlights

May 04, 2023

From Prothena Corporation plc

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

May 04, 2023

Via Benzinga

Prothena Corp Earnings Preview ↗

May 03, 2023

Via Benzinga

Another Sucess In Alzheimer’s Disease ↗

May 03, 2023

Eli Lily reported a successful phase III trial of donanemab in Alzheimer’s Disease. How does it differentiate from lecanemab and what does it mean for beta-amyloid treatments?

Via Talk Markets

Prothena to Report First Quarter 2023 Financial Results on May 4

April 27, 2023

From Prothena Corporation plc

Via Business Wire

Where Prothena Corp Stands With Analysts ↗

April 24, 2023

Via Benzinga

The Latest Analyst Ratings for Prothena Corp ↗

April 03, 2023

Via Benzinga

Earnings Outlook For Prothena Corp ↗

February 22, 2023

Via Benzinga

Prothena Touts Encouraging Data From Early-Stage Alzheimer's Candidate ↗

February 01, 2023

Via Benzinga

Prothena to Participate in 2023 Bank of America Healthcare Conference

April 24, 2023

From Prothena Corporation plc

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023 ↗

April 24, 2023

Via Benzinga

Analyst Expectations for Prothena Corp's Future ↗

December 21, 2022

Via Benzinga

Cantor Fitzgerald Maintains Overweight Rating for Prothena Corp: Here's What You Need To Know ↗

December 21, 2022

Via Benzinga

Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial

April 13, 2023

From Walgreens

Via Business Wire

Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023

March 31, 2023

From Prothena Corporation plc

Via Business Wire

Prothena to Participate in Stifel 2023 Virtual CNS Days

March 21, 2023

From Prothena Corporation plc

Via Business Wire

Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode

March 15, 2023

FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 15, 2023 – USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for...

Via FinancialNewsMedia

Prothena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting

March 14, 2023

From Prothena Corporation plc

Via Business Wire

Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights

February 23, 2023

From Prothena Corporation plc

Via Business Wire

Earnings Scheduled For February 23, 2023 ↗

February 23, 2023

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.

Via Benzinga

Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

February 16, 2023

From Prothena Corporation plc

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

February 14, 2023

Via Benzinga

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 03, 2023

From Prothena Corporation plc

Via Business Wire

Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease

January 31, 2023

From Prothena Corporation plc

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023 ↗

January 27, 2023

Via Benzinga

Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish ↗

January 11, 2023

2023 can be the year of biotechs after two consecutive years of negative or barely positive returns.

Via Talk Markets

How To Weather These Choppy Markets ↗

December 22, 2022

Until we get an absolute bottom in the markets, the best way to avoid experiencing a devastating permanent loss of capital is to keep away from stocks with deteriorating fundamentals and heavy insider...

Via Talk Markets

Top Biotech Companies Are Making Steady Progress In Developing Treatments To Fight Alzheimer’s Disease ↗

December 21, 2022

The estimated cost of Alzheimer's disease and related dementia (ADRD) care in 2021 was $355 billion. Investing in the top companies that are making steady progress toward developing a treatment for...

Via Talk Markets

Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares

December 14, 2022

From Prothena Corporation plc

Via Business Wire

Why Prothena Shares Are Trading Lower ↗

December 14, 2022

Prothena Corporation PLC (NASDAQ: PRTA) shares are trading lower by 6.53% to $59.10 during Wednesday morning. The company announced that it has commenced an underwritten public offering of 3,000,000 of...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.